OncologyTube.com is the first and only free video sharing website dedicated to helping oncology professionals spread knowledge about cancer research through video, audio and other multimedia.
    • OncologyTube Cancer Articles, News and Videos

      Site: OncologyTube Cancer Articles, News and Videos

    • Products & Pricing
      • Banner Advertising Plans
      • eNewsletter Packages
      • Pre-Roll Advertising
      • Create A Deep Dive Conversation
      • Create a Video Release (VR)
      • Boost Earned Media Only $60
    • 0
      • Portuguese
      • Spanish
      • Italian
      • Greek (Greece)
      • Sinhala
      • Polish
      • Arabic (Saudi Arabia)
      • Swedish (Sweden)
      • Portuguese (Brazil)
      • Hindi (India)
      • English (Australia)
      • Hebrew (Israel)
      • Czech
      • Chinese
      • Turkish
      • Japanese (Japan)
      • Dutch
      • French
      • German
      • Chinese (Traditional Han, Taiwan)
      • Korean (South Korea)
      • Thai
      • Spanish (Chile)
      • English (United States)
      • Russian
      • Danish (Denmark)
  • ホーム
  • トレンド

  • ログイン

  • Quick Links
  • Schedule A Remote Interview!
  • Check Out Our Blog
  • Buy Advertising Banners
  • Buy Pre-Roll Advertisements
  • Boost Your Earned Media starting at Just $60
  • Create A Deep Dive Conversation
  • Advertising Specifications
  • Our Editorial Process

  • オーディオと動画
  • 動画
  • オーディオ

  • チャンネル
  • チャンネル一覧

  • カテゴリー
  • Acute Lymphoblastic Leukemia 5588
  • Acute Myelogenous Leukemia 222
  • Bladder 96
  • Bone Metastases 5
  • Brain 79
  • Breast 523
  • Business Management 5
  • Cervical 16
  • Chronic Lymphocytic Leukemia 208
  • Chronic Myelogenous Leukemia 54
  • Colorectal 169
  • Conference Coverage 1
  • COVID-19 43
  • Gastrointestinal 177
  • General 341
  • Genitourinary 3
  • Head and Neck 110
  • ヘルプ 3
  • Hematologic Malignancies 204
  • Hodgkin Lymphoma 31
  • Imaging 2
  • Immunotherapy 179
  • Kidney 392
  • Liver 40
  • Lung 89
  • Lymphoma 232
  • Melanoma and Skin 107
  • Multiple Myeloma 533
  • Myeloproliferative Disease 37
  • News 149
  • Non-Hodgkin Lymphoma 81
  • Non-Small Cell Lung Cancer 551
  • Other 517
  • Ovarian 65
  • Pancreatic 100
  • Patient Resources 51
  • Pediatric 7
  • Prostate 300
  • Sarcoma 13
  • Sickle Cell 22
  • Small Cell Lung Cancer 81
  • Supportive Care 51
  • Testicular 3
  • Urology 16
  • Uterine 9

  • Install
  • Play a Link
  • 概要
  • お問い合わせ
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Bladder
  • Bone Metastases
  • Brain
  • Breast
  • Business Management
  • Cervical
  • Chronic Lymphocytic Leukemia
  • Chronic Myelogenous Leukemia
  • Colorectal
  • Conference Coverage
  • COVID-19
  • Gastrointestinal
  • General
  • Genitourinary
  • Head and Neck
  • ヘルプ
  • Hematologic Malignancies
  • Hodgkin Lymphoma
  • Imaging
  • Immunotherapy
  • Kidney
  • Liver
  • Lung
  • Lymphoma
  • Melanoma and Skin
  • Multiple Myeloma
  • Myeloproliferative Disease
  • News
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • Other
  • Ovarian
  • Pancreatic
  • Patient Resources
  • Pediatric
  • Prostate
  • Sarcoma
  • Sickle Cell
  • Small Cell Lung Cancer
  • Supportive Care
  • Testicular
  • Urology
  • Uterine
Roswell Park Moving Unique Immunotherapy Platform Forward With $6.42 Million DoD Grant

Roswell Park Moving Unique Immunotherapy Platform Forward...

New multi-pronged strategy for treating advanced breast cancer earns Breakthrough Award

  • Multifaceted approach combines 3 complementary immunotherapy strategies
  • Two clinical trials slated for 2020 in patients with metastatic breast cancer
  • Platform combines biologic agents to make tumors visible to immune system
     

BUFFALO, N.Y. — A team from Roswell Park Comprehensive Cancer Center is moving a new three-part strategy for treating advanced cancers forward with support from a U.S. Department of Defense (DoD) grant to Pawel Kalinski, MD, PhD, Vice Chair for Translational Research and Rustum Family Professor for Molecular Therapeutics and Translational Research at the Buffalo, N.Y.-based cancer center. The four-year, $6.42 million Breakthrough Award through the DoD’s Breast Cancer Research Program will fund a clinical trial in patients with brain-metastatic breast cancer, to be led by Shipra Gandhi, MD, Assistant Professor of Oncology in the Department of Medicine at Roswell Park.

The phase II trial, slated to open in 2020, would be the first clinical study to assess the effectiveness of a three-pronged strategy combining distinct immunotherapy approaches:
  • A new dendritic-cell treatment vaccine developed by Dr. Kalinski and colleagues in collaboration with Brian Czerniecki, MD, PhD, Chair of the Breast Oncology Department at Moffitt Cancer Center in Tampa, Florida
  • Chemokine modulation using a combination proposed and validated by Dr. Kalinski as an optimized adjuvant for dendritic-cell vaccines, incorporating rintatolimod (brand name Ampligen) and interferon alfa-2b (brand name Intron A)
  • Immune checkpoint inhibition 
gandhi_kalinski_2019_crop.jpg?itok=MXQtI3V1
Drs. Shipra Gandhi and Pawel Kalinski will lead a Department of Defense-funded clinical trial assessing a three-pronged immunotherapy strategy for metastatic breast cancer.

Alone, these therapies are effective for a limited number of patients, but evidence suggests that together they may help break through a persistent challenge in oncology: how to turn “cold” tumors that don’t respond to existing therapies into “hot” ones that the immune system can be trained to recognize and pursue.

“A major limitation of cancer immunotherapy is that tumors adapt to naturally occurring effector cells by shutting down production of the relevant chemokines in the tumor microenvironment,” says Dr. Kalinski, the overall Principal Investigator for the project. “Our strategy uses a unique combination of biologic agents to make tumors visible to the immune system by making them look like tissue that’s been infected by a virus. We’ve never tested them all together before in patients, but the findings from earlier clinical and preclinical studies lend strong support for assessing this combination even in the most aggressive and hard-to-treat cancer types.”

Three key factors distinguish this platform for combination immunotherapy:

  • The approach is tumor-selective, meaning it can act preferentially to generate responses only in cancer tissues, but not in normal, noncancerous tissue
  • It selectively activates so-called “good” chemokines in the tumor microenvironment and promotes selective attraction of desirable tumor-fighting immune cells, but avoids activating “bad” chemokines that attract undesirable suppressive cells
  • These therapies have been shown in preclinical and clinical trials to be associated with low toxicity and few adverse side effects

The team will study this approach first in patients with localized brain-metastatic breast cancer (BMBC), or breast cancer that has begun to spread to the brain but is not yet widely disseminated. A companion clinical trial in patients with disseminated, leptomeningeal BMBC, to be led by Peter A. Forsyth, MD, Chair of the Neuro-Oncology Department at Moffitt Cancer Center, in collaboration with Dr. Czerniecki, partnering Principal Investigator on the project, will move forward with additional DoD funding of more than $8 million. Both trials will be available to patients at Roswell Park and at Moffitt.

“There are currently no curative treatments for breast cancer that has spread to and grown in the brain, and the options we have often involve significant side effects or harm to healthy tissues. So this is an area of pronounced clinical need,” notes Dr. Gandhi, Principal Investigator on the Roswell Park study. “We’re particularly encouraged to be developing a strategy that has the potential to be effective for patients with various breast cancer subtypes — cancers that are positive for HER2 markers as well as notoriously aggressive triple-negative breast cancers.”

Roswell Park has three other studies in progress assessing some of the component elements of this new therapeutic platform:

  • Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients with Colorectal Cancer Metastatic to the Liver (NCT03403634 – actively recruiting)
  • Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients with Prostate Cancer Before Surgery (NCT NCT03899987 – authorized by the FDA and Roswell Park’s Internal Review Board; not yet recruiting)
  • Chemokine Modulation Therapy and Pembrolizumab in Treating Participants with Metastatic Triple-Negative Breast Cancer (NCT NCT03599453 – actively recruiting)

AIM ImmunoTech Inc. has agreed to provide rintatolimod for the new DoD-funded studies in brain-metastatic breast cancer, as well as these ongoing studies.

Dr. Kalinski gratefully acknowledges earlier support for his work through donations to Roswell Park as a critical foundation that allowed him to pursue and attract outside funding for this work.

The new study in patients with BMBC is not yet open to accrual. For information about other clinical trials currently available at Roswell Park, please visit roswellpark.org/clinical-trials, call 1-800-ROSWELL (1-800-767-9355) or contact Roswell Park by email at askroswell@roswellpark.org.

###

For an online version of this release, please visit: https://www.roswellpark.org/media/news/roswell-park-moving-unique-immunotherapy-platform-forward-642-million-dod-grant



Source: Roswell Park Comprehensive Cancer Center

open?upn=XsimBmU6vYsZ-2BKrRy-2F67493xR-2BFOOLjX6Wq20b6qrEEJYJben93pdi7xuFz-2F8NSjWfAP1A9-2FsdHhmXrkb8KRw6gn7NIyqA1eEbcBa13-2FK01FW0RyChd-2FZ6i0-2BihpmG5spk42tStCM-2BJ7VhLLMSZt-2BAjhjBZ-2Fpuds25pkLZ5DHeVeJN1dApeTdVVm-2Fke0-2FEZoe988YzpV4bMwVTSd3LOtqr1aRmtfMsw7ayhlRv3qtoT31EewPQ-2B0FUbNuZv2v6XjT0nFN6YqkvUQQDGx5f-2FNIkKGdCQlJOB4Q8Eeju42R7dsJcLyMz5iUb4yGg3WsGwUoP42GYU8Y2As2XnXqtVP5Nz8JxG7AiqksnRLtgL4ZLw-3D

35 ビュー
前 3 年
Cancer
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン

Immunotherapy

PRO in Pts With Rare Cancers: Pembrolizumab [2022]
0:11:56
PRO in Pts With Rare Cancers: Pembrolizumab [2022]
96 ビュー
前 4 ヵ月
National Cancer Institute
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Disparities in Immunotherapy Cancer Care
0:19:52
Disparities in Immunotherapy Cancer Care
15 ビュー
前 6 ヵ月
ACHL
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
EXUMA Biotech's Subcutaneous CAR-TaNK and In Vivo CAR Cell And Gene Therapy Programs @EXUMABiotech #celltherapy #genetherapy #biotech
0:18:47
EXUMA Biotech's Subcutaneous CAR-TaNK and In Vivo CAR Cel...
269 ビュー
前 8 ヵ月
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Podcast Xianxin Hua, MD, PhD @PennMedicine #CDH17CART CDH17CAR T Cells:  NETs and GI Cancers
0:10:53
Podcast Xianxin Hua, MD, PhD @PennMedicine #CDH17CART CDH...
60 ビュー
前 10 ヵ月
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Xianxin Hua, MD, PhD @PennMedicine #CDH17CART CDH17CAR T Cells:  NETs and GI Cancers
0:10:53
Xianxin Hua, MD, PhD @PennMedicine #CDH17CART CDH17CAR T ...
101 ビュー
前 10 ヵ月
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Podcast Mehmet Altan, MD @mehmetaltan @MDAndersonNews @ANaingMD @HajjarJoud #Immunotherapy Pulmonary Toxicities of Immunotherapy
0:03:29
Podcast Mehmet Altan, MD @mehmetaltan @MDAndersonNews @AN...
16 ビュー
前 11 ヵ月
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Mehmet Altan, MD @mehmetaltan @MDAndersonNews @ANaingMD @HajjarJoud #Immunotherapy Pulmonary Toxicities of Immunotherapy
0:03:29
Mehmet Altan, MD @mehmetaltan @MDAndersonNews @ANaingMD @...
52 ビュー
前 11 ヵ月
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Podcast Rebecca Harrison, MD @ANaingMD @HajjarJoud @MDAndersonNews @BCCancer #Immunotherapy #NeuroOncology Neurologic Toxicities of Immunotherapy
0:06:54
Podcast Rebecca Harrison, MD @ANaingMD @HajjarJoud @MDAnd...
76 ビュー
前 11 ヵ月
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Rebecca Harrison, MD @ANaingMD @HajjarJoud @MDAndersonNews @BCCancer #Immunotherapy #NeuroOncology Neurologic Toxicities of Immunotherapy
0:06:54
Rebecca Harrison, MD @ANaingMD @HajjarJoud @MDAndersonNew...
209 ビュー
前 11 ヵ月
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Podcast Nazanin Majd, MD @NazMajd @MDAndersonNews @ANaingMD @HajjarJoud #Immunotherapy #NeuroOncology Immunotherapy For Neuro-Oncology
0:07:35
Podcast Nazanin Majd, MD @NazMajd @MDAndersonNews @ANaing...
38 ビュー
前 1 年
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Nazanin Majd, MD @NazMajd @MDAndersonNews @ANaingMD @HajjarJoud #Immunotherapy #NeuroOncology Immunotherapy For Neuro-Oncology
0:07:35
Nazanin Majd, MD @NazMajd @MDAndersonNews @ANaingMD @Hajj...
39 ビュー
前 1 年
Cancer News
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン
Podcast Augusto Villanueva, MD @augustoNYC @MountSinaiLiver @TischCancer #ASCOGI22 #GI22 #HCC Immunotherapy: Early-Stage HCC
0:09:07
Podcast Augusto Villanueva, MD @augustoNYC @MountSinaiLiv...
29 ビュー
前 1 年
Gastrointestinal GI Cancer Meeting
追加
後で再度視聴しますか?
この動画を再生リストに追加するには、サインインしてください ログイン

Copyright 2023 Medicus Networks, Inc. 45121 Morgan Heights Rd. Temecula, CA 92592